Search Results - "Cheema, Puneet"

Simultaneous sludge minimization, pollutant and nitrogen removal using integrated MBBR configuration for tannery wastewater treatment by Sodhi, Vijay, Singh, Charanjit, Pal Singh Cheema, Puneet, Sharma, Reena, Bansal, Ajay, Kumar Jha, Mithilesh

“…[Display omitted] •An integrated MBBR configuration for tannery influent treatment was demonstrated.•AMOMOX process implementation enabled 42.6% of sludge…”
Get full text

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin by List, Alan F, Sun, Zhuoxin, Verma, Amit, Bennett, John M, Komrokji, Rami S, McGraw, Kathy, Maciejewski, Jaroslaw, Altman, Jessica K, Cheema, Puneet S, Claxton, David F, Luger, Selina M, Mattison, Ryan J, Wassenaar, Timothy R, Artz, Andrew S, Schiffer, Charles A, Litzow, Mark R, Tallman, Martin S

“…Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with…”
Get full text

CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108 by Stearns, Vered, ONeill, Anne, Schneider, Bryan P, Skaar, Todd C, Liu, Minetta C, Lohrisch, Caroline, Goetz, Matthew P, Vallejos, Carlos S, Sparano, Joseph A, Villa, Diego, Silverman, Paula, Cheema, Puneet S, Moore, Jr, Dennis F, Sledge, Jr, George W

“…In tamoxifen-treated individuals, reduced-function genetic variants in the CYP2D6 gene or inhibition of the enzyme result in low circulating endoxifen…”
Get full text

Characterization and prediction of stormwater runoff quality in sub-tropical rural catchments by Cheema, Puneet Pal Singh, Reddy, Akepati S., Kaur, Sukhpreet

“…Due to scarcity of local data on stormwater pollution levels and rainfall-runoff generation process, very few attempts have been made towards the management of…”
Get full text

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203) by Meropol, Neal J., Feng, Yang, Grem, Jean L., Mulcahy, Mary F., Catalano, Paul J., Kauh, John S., Hall, Michael J., Saltzman, Joel N., George, Thomas J., Zangmeister, Jeffrey, Chiorean, Elena G., Cheema, Puneet S., O'Dwyer, Peter J., Benson, Al B.

“…BACKGROUND The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with low thymidylate synthase (TS‐L) expression would…”
Get full text

Implementation analysis of solid waste management in Ludhiana city of Punjab by Mir, Ishfaq Showket, Cheema, Puneet Pal Singh, Singh, Sukhwinder Pal

“…•Solid waste management (SWM) in Ludhiana is worse affected.•Factors affecting SWM are evaluated by importance-performance analysis.•Political neglect, public…”
Get full text

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102 by Kornblum, Noah, Zhao, Fengmin, Manola, Judith, Klein, Paula, Ramaswamy, Bhuvaneswari, Brufsky, Adam, Stella, Phillip J, Burnette, Brian, Telli, Melinda, Makower, Della F, Cheema, Puneet, Truica, Cristina I, Wolff, Antonio C, Soori, Gamini S, Haley, Barbara, Wassenaar, Timothy R, Goldstein, Lori J, Miller, Kathy D, Sparano, Joseph A

“…Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian target of rapamycin pathway, a…”
Get full text

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers by Shroff, Rachna T., Guthrie, Katherine A, Scott, Aaron James, Borad, Mitesh J., Goff, Laura Williams, Matin, Khalid, Mahipal, Amit, Kalyan, Aparna, Javle, Milind M., Aghajanian, Carol, Tan, Benjamin R., Cheema, Puneet S., Patel, Anuj K., Iyer, Renuka V., Kelley, Robin Kate, Thumar, Jaykumar Ranchodbhai, El-Khoueiry, Anthony B., Chiorean, E. Gabriela, Hochster, Howard S., Philip, Philip Agop

“…LBA490 Background: Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Gemcitabine-based regimens are the standard…”
Get full text

Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study by Perez, Giselle K., Hong, Fangxin, Evens, Andrew M., Habermann, Thomas M., Advani, Ranjana, Ansell, Stephen M., Cheema, Puneet S., Dy, Philip A., O'Brien, Timothy E., Winter, Jane N., Chang, Julie E., Cella, David, Kahl, Brad S., Wagner, Lynne I.

“…Introduction: FL is the most common indolent non-Hodgkin lymphoma in the Western world. FL may cause disease-related symptoms, and patients with high-risk…”
Get full text

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 by Evens, Andrew M, Hong, Fangxin, Habermann, Thomas M, Advani, Ranjana H, Gascoyne, Randy D, Witzig, Thomas E, Quon, Andrew, Ranheim, Erik A, Ansell, Stephen M, Cheema, Puneet Singh, Dy, Philip A, O'Brien, Timothy E, Winter, Jane N, Cescon, Terrence P, Chang, Julie E, Kahl, Brad S

“…We sought to improve upon frontline bendamustine/rituximab (BR) induction therapy followed by rituximab maintenance in untreated high-risk follicular lymphoma…”
Get full text

A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 by Evens, Andrew M., Hong, Fangxin, Habermann, Thomas M., Advani, Ranjana H., Gascoyne, Randy D., Witzig, Thomas E., Quon, Andrew, Ranheim, Erik, Ansell, Stephen M., Cheema, Puneet Singh, Dy, Philip A., O’Brien, Timothy E., Winter, Jane N., Cescon, Terrence P., Chang, Julie E., Kahl, Brad S.

Get full text

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health by List, Alan F., Sun, Zhuoxin, Verma, Amit, Bennett, John M., McGraw, Kathy, Maciejewski, Jaroslaw P., Komrokji, Rami S., Wassenaar, Timothy R., Luger, Selina M., Mattison, Ryan J., Cheema, Puneet S., Altman, Jessica K., Claxton, David F., Schiffer, Charles A., Artz, Andrew S., Litzow, Mark, Tallman, Martin S.

“…Background: Only a small subset of Lower risk (LR) MDS patients benefit from treatment with rhu-Erythropoietin (Epo). We previously reported that lenalidomide…”
Get full text

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group by Evens, Andrew M, Hong, Fangxin, Habermann, Thomas M, Advani, Ranjana H., Gascoyne, Randy D., Witzig, Thomas E, Quon, Andrew, Ranheim, Erik A., Cheema, Puneet, Dy, Philip, O'Brien, Timothy E., Winter, Jane N., Cescon, Terrence Paul, Chang, Julie, Kahl, Brad S

“…Background: The BIONIC study tested whether bortezomib (V) improved the complete remission (CR) rate when added to standard bendamustine/rituximab (BR)…”
Get full text

Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E4203) by Meropol, Neal J., Feng, Yang, Grem, Jean L., Mulcahy, Mary F., Catalano, Paul J., Kauh, John S., Hall, Michael J., Saltzman, Joel N., George, Thomas J., Zangmeister, Jeffrey, Chiorean, Elena G., Cheema, Puneet S., O’Dwyer, Peter J., Benson, Al B.

“…Colorectal cancer patients were assigned treatment based on thymidylate synthase protein (TS) expression (low versus high) in tumor tissue to a combination…”
Get full text

Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health by List, Alan F, Sun, Zhuoxin, Verma, Amit, Bennett, John M., McGraw, Kathy L, Nardelli, Lisa Ann, Maciejewski, Jaroslaw P, Altman, Jessica K, Cheema, Puneet, Claxton, David F., Komrokji, Rami S., Luger, Selina, Mattison, Ryan, Wassenaar, Tim, Artz, Andrew, Schiffer, Charles A, Tallman, Martin S.

“…▪ Background: Treatment with rhu-Epo ameliorates anemia in a subset of LR-MDS patients, however, effective salvage therapy is limited. LEN promotes erythroid…”
Get full text

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408) by Evens, Andrew M., Hong, Fangxin, Habermann, Thomas Matthew, Advani, Ranjana H., Gascoyne, Randy D., Witzig, Thomas E., Quon, Andrew, Wagner, Lynne I., Ansell, Stephen Maxted, Petrich, Adam Matthew, Chang, Julie E., O'Brien, Timothy E., Cheema, Puneet S., Cescon, Terrence, Sturtz, Keren, Kahl, Brad S.

“…Abstract only…”
Get full text

Prediction and early detection of anthracycline-related cardiotoxicity using cardiac biomarkers by Stevens, Patrick Lawson, Lenihan, Daniel John, Ky, Bonnie, Warneke, Carla L., Johnson, Marcy M, Abramson, Vandana Gupta, Mayer, Ingrid A., Adams, Paul T., Campbell, Mark G., Cheema, Puneet S., Moore, Dennis Frederic, Yeshwant, Chilakamarri, Carver, Joseph R., Fisch, Michael

“…Abstract only…”
Get full text

Panitumumab Monotherapy in Patients with Metastatic Colorectal Cancer and Cetuximab Infusion Reactions: A Series of Four Case Reports by Langerak, Alan, River, George, Mitchell, Edith, Cheema, Puneet, Shing, Mona

“…Abstract Purpose Monoclonal antibodies against the epidermal growth factor receptor approved for treating metastatic colorectal cancer (mCRC) include cetuximab…”
Get full text

Clinical risk prediction in anthracycline cardiotoxicity by Ky, Bonnie, Warneke, Carla L., Lenihan, Daniel John, Cheema, Puneet S., Moore, Dennis Frederic, Campbell, Mark G., Yeshwant, Chilakamarri, Adams, Paul T., Krone, Ron, Carver, Joseph R., Nasta, Sunita, Svoboda, Jakub, Schuster, Stephen J., Reddy, Nishitha M., Patel, Sunil M., Rieber, Alyssa G., Johnson, Marcella M, Fisch, Michael

“…Abstract only…”
Get full text

Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows by Mundle, S D, Mativi, B Y, Bagai, K, Feldman, G, Cheema, P, Gautam, U, Reza, S, Cartlidge, J D, Venugopal, P, Shetty, V, Gregory, S A, Robin, E, Rifkin, S, Shah, R, Raza, A

“…In this study, we examined the role of Fas-signaling in the apoptotic pathway in myelodysplastic syndromes (MDS). Ficoll-separated mononuclear cells from 18…”
Get more information